AMTI - How Russia's invasion of Ukraine may impact pharma-biotech R&D

As the Russian invasion of Ukraine continues, several pharma and biotech companies have exposure to both countries through clinical trials being conducted there. One biotech, Karuna Therapeutics (NASDAQ:KRTX), has already said the disturbance has impacted a late-stage trial. On Thursday, the company indicated that a top-line data readout of the EMERGENT-3 trial of KarXT for schizophrenia expected in the second half of this year may not happen. The study is ongoing in the U.S. and Ukraine. Jefferies analyst Chris Howerton noted that any delays in Ukraine may not have as big an impact as feared if data from the EMERGENT-2 trial, which has U.S. sites only, has a positive readout around mid-year. Howerton added that several other small biotechs he follows have at least some exposure to Ukraine: Applied Molecular Transport (NASDAQ:AMTI), Intra-Cellular Therapies (NASDAQ:ITCI), TG Therapeutics (NASDAQ:TGTX), and Veru (NASDAQ:VERU). For example, Veru (VERU) has a phase 3 trial evaluating enobosarm in

For further details see:

How Russia's invasion of Ukraine may impact pharma-biotech R&D